Sigma Planning Corp’s Teva Pharmaceuticals TEVA Stock Holding History

Sigma Planning Corp’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-13,483	Closed	-$123K	–	1355
2022 Q4	$123K	Hold	13,483	–	–	﹤0.01%	1177
2022 Q3	$109K	Buy	+13,483	New	+$119K	﹤0.01%	1190
2021 Q4	–	Sell	-10,043	Closed	-$98K	–	1468
2021 Q3	$98K	Buy	+10,043	New	+$94K	﹤0.01%	1319
2018 Q4	–	Sell	-9,896	Closed	-$213K	–	969
2018 Q3	$213K	Sell	9,896 -1,000	-9%	-$23.2K	0.01%	858
2018 Q2	$265K	Sell	10,896 -2,446	-18%	-$49.9K	0.02%	703
2018 Q1	$228K	Buy	13,342 +2,037	+18%	+$39.8K	0.02%	727
2017 Q4	$214K	Buy	+11,305	New	+$170K	0.02%	752
2017 Q1	–	Sell	-23,255	Closed	-$843K	–	815
2016 Q4	$843K	Buy	23,255 +12,551	+117%	+$501K	0.09%	237
2016 Q3	$493K	Buy	10,704 +484	+5%	+$25.3K	0.06%	348
2016 Q2	$513K	Buy	+10,220	New	+$544K	0.07%	317
2015 Q2	–	Sell	-3,347	Closed	-$209K	–	767
2015 Q1	$209K	Sell	3,347 -172	-5%	-$10K	0.03%	658
2014 Q4	$202K	Buy	+3,519	New	+$196K	0.03%	632

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

IAM

Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

Sigma Planning Corp's TEVA Position: Q1 2023 in Review

Sigma Planning Corp sold out of Teva Pharmaceuticals (TEVA) in Q1 2023, closing a stake of 13,483 shares — an estimated $123K sold.

Sigma Planning Corp first reported a position in TEVA in Q4 2014 and held it in 12 quarters. The position peaked at $843K in Q4 2016. 438 funds tracked by Wall St. Rank hold TEVA as of Q1 2023.

Sigma Planning Corp reported no remaining Teva Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Sigma Planning Corp sold 13,483 Teva Pharmaceuticals shares in Q1 2023, an estimated $123K.
Sigma Planning Corp first reported a position in Teva Pharmaceuticals in Q4 2014 and held it in 12 quarters.
Sigma Planning Corp's Teva Pharmaceuticals position peaked at $843K in Q4 2016.
438 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2023.

Based on Sigma Planning Corp's 13F filing for Q1 2023, filed 8 May 2023.